Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kura Oncology ( (KURA) ) has shared an update.
Stephen Dale, M.D. resigned as Chief Medical Officer of Kura Oncology to focus on personal health, leading to a settlement agreement entitling him to compensation and extended stock option exercise periods. Following his resignation, Kura Oncology appointed Mollie Leoni, M.D. as Chief Medical Officer and Francis Burrows, Ph.D. as Chief Scientific Officer, indicating a strategic leadership change.
More about Kura Oncology
Kura Oncology is a company operating in the biotechnology industry, focusing on the development of precision medicines for the treatment of cancer.
YTD Price Performance: 0.58%
Average Trading Volume: 1,640,118
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $678.9M
See more insights into KURA stock on TipRanks’ Stock Analysis page.